News Roche joins the oral SERD club as FDA clears Wilserdly Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for its Wilserdly product.
News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
News Gazyva is first FDA-cleared drug for rare disease pMN Patients in the US with primary membranous nephropathy have a first approved drug, after the FDA cleared Roche's Gazyva for the rare kidney disorder.
News ESMO26: Roche's KRAS drug tops approved drugs in NSCLC In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.
News Roche posts solid results ahead of looming patent cliff Roche's Q3 pharma sales rose a healthy 7%, although the first signs of weakness for blockbuster product Xolair are a warning of tougher times ahead.
News Roche offers $15bn for strategic-level deal with Hansoh A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.